This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Strength Seen in CoDiagnostics, Inc. (CODX): Can Its 9.7% Jump Turn into More Strength?
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are Investors Undervaluing CoDiagnostics, Inc. (CODX) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Value Investor Highlights: Hibbett Sports, CoDiagnostics, Quidel Corp, DHT Holdings and Rocket Companies
by Zacks Equity Research
Zacks Value Investor Highlights: Hibbett Sports, CoDiagnostics, Quidel Corp, DHT Holdings and Rocket Companies
Screening for Ben Graham Value Stocks
by Tracey Ryniec
What kind of value stocks would Ben Graham, the father of value investing, be looking at in 2021?
CoDiagnostics, Inc. (CODX) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 30.00% and 2.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
CoDiagnostics, Inc. (CODX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CoDiagnostics, Inc. (CODX) Q4 Earnings Lag Estimates
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -12.24% and 1.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics (CODX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Co-Diagnostics' (CODX) third-quarter results are likely to reflect higher COVID-19 test sales.
CoDiagnostics, Inc. (CODX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) closed the most recent trading day at $14.42, moving +0.07% from the previous trading session.
Implied Volatility Surging for Co-Diagnostics (CODX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Co-Diagnostics (CODX) stock based on the movements in the options market lately.
Company News for Oct 5, 2020
by Zacks Equity Research
Companies in the news are: UBER, WMT, BBBY, CODX
CoDiagnostics, Inc. (CODX) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -29.51% and -10.96%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics (CODX) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Co-Diagnostics' (CODX) second-quarter results are likely to reflect higher COVID-19 test sales.
CoDiagnostics, Inc. (CODX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CoDiagnostics, Inc. (CODX) closed at $25.73, marking a -1.61% move from the previous day.
CoDiagnostics, Inc. (CODX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CoDiagnostics, Inc. (CODX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CoDiagnostics, Inc. (CODX) closed at $22.12, marking a +1.37% move from the previous day.
Advanced Micro Devices, Under Armour, Immunomedics, GenMark and Co-Diagnostics highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Advanced Micro Devices, Under Armour, Immunomedics, GenMark and Co-Diagnostics highlighted as Zacks Bull and Bear of the Day
Rising Coronavirus Cases Spark Lockdown Fears: 5 Defensive Picks
by Zacks Equity Research
Given the current coronavirus scenario, investors can invest in defensive stocks that can return well even during phases of market volatility
3 Inexpensive MedTech Gainers of 2H20 Beyond TMO and RMD
by Zacks Equity Research
Here we look at three cheap MedTech stocks that investors can take a look at apart from giants like Thermo Fisher and ResMed that are expensive.
CoDiagnostics, Inc. (CODX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) closed at $18.19 in the latest trading session, marking a +1% move from the prior day.
Is CoDiagnostics (CODX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (CODX) Outperforming Other Medical Stocks This Year?
CoDiagnostics, Inc. (CODX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) closed the most recent trading day at $19.46, moving +0.57% from the previous trading session.
CoDiagnostics, Inc. (CODX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, CoDiagnostics, Inc. (CODX) closed at $18.23, marking a +0.05% move from the previous day.
Has CoDiagnostics (CODX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CODX) Outperforming Other Medical Stocks This Year?
Harrow Health (HROW) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Harrow Health (HROW) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.